4Holloway K P,Rouphael N G,well S J B,et al.PloymyxmB and dox-ycycline use inpatients with multidrug—resistant Acinetobacter baumannii infection in the intensive care unite.[J].Pharmacother,2006,90(18):1939-1945.
5Huys,Conckaertm,Vaneechouttem,et al.distribution of tetra-cyclineresistance gene in genotypically related and unrelated multiresistanceAcinetobacter baumannii strelins from different European.hospitals[J].Remicrobiol,2005,156(3):348-355.
3Consales G,Grmignie E,Zamidei L, et al. A multidrug-resistant Acine tobacter baumanii outbreak in intensive care unit :antimicrobiai and or- ganizational strategies[J]. J Crit Care,2011,26(5) :453-459.
4Choi WS, Kim SH, Jeon EG, et al. Nosocomial outbreak of car- bapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program [ J ]. J Korean Med Sci, 2010.25 ( 7 ) :999-1004.
5Chopra T, Marchaim D, Awali RA, et al. Epidemiology of blood- stream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes [ J]~. Antimicrob Agents Chemother, 2013,57 (12) :6270-6275.
6Pogue JM, Mann T, Barber KE, et al. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and manage- ment [ J]. Expert Rev Anti Infect Ther, 2013,11 (4) :383-393.
7Mezzatesta ML, D'Andrea MM, Migliavacca R, et al. Epidemio- logical characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy [ J]. Clin Micro- biol Infect, 2012,18 (2) : 160-166.
